Analystreport

Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $20.00 price target on the stock.

Aeglea BioTherapeutics, Inc.  (AGLE) 
Last aeglea biotherapeutics, inc. earnings: 8/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aegleabio.com/investor-overview